A new blood test for women with breast cancer could identify more women who will benefit from the targeted treatment Herceptin without the need for uncomfortable biopsies. The new 'liquid biopsy' uses cutting-edge genetic techniques to detect breast cancer DNA in the bloodstream, and was developed by a team at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust...
More...
Linear Mode
